Printer Friendly

Visual manifestations.

It is well known that hyperbaric oxygen therapy can have an effect Ion eyesight and produce visual manifestations in some patients. High levels of oxygen under pressure for extended periods of time can affect the Central Nervous System (CNS) resulting in oxygen toxicity. The visual side effects of oxygen toxicity are twitching of the eyelids and blurred vision. Less common is visual constriction and hallucinations. The reasons for these effects are uncertain but this toxicity may be the result of oxygen metabolism and the production of superoxide radicals (radicals damage cells, proteins and DNA by altering their chemical structure). Radicals are usually kept in check by cellular defense mechanisms but these may be overwhelmed in the present of such high oxygen levels. The most common defender is called superoxide dismutase, which is an antioxidant enzyme. CNS oxygen toxicity can occur quickly during oxygen exposure but can subside quickly by removing the patient from the high oxygen environment. It is impossible to predict which patient may be affected although factors such a treatment pressure and duration among others, can increase or decrease the risk. The same patient may be treated 20 times and experience no effects of oxygen toxicity until treatment number 21, and then experience no further episodes. Hyperbaric treatment can be initiated shortly after the effects subside (15 minutes) but our practice is to end the treatment and continue the next day. Another type of oxygen toxicity affects the retina of the eye, in which the patient experiences a decrease in their peripheral vision. This type is very rare and reversible once oxygen exposure is stopped.


The most common type of oxygen toxicity is lenticular or affecting the lens. This phenomenon is called progressive myopia, a condition represented by defective vision of distant objects, also called nearsightedness. The number of hyperbaric treatments administered increases its occurrence and this is usually not seen when less than 20 treatments are given. Treatments are usually 90 to 1 20 minute in length and given on a daily basis at 2.0 ATA or higher. The incidence is reported to be between 20 to 40% and more often seen in diabetic and elderly patient. The good news is that when hyperbaric therapy is finished the condition is reversed. Complete recovery usually takes about 6 weeks although it may take longer in some cases. This condition is always discussed with patients so they realize that is not uncommon and that it is reversible. For this reason, patients are told not to get a new eyeglass prescription until about 6 weeks after therapy has ended. For patients with presbyopia, their condition may improve. They normally have an inability to focus sharply on items that are close (like with us middle-aged people who have trouble reading). Unfortunately this improvement will also reverse itself after therapy is terminated.

Cataract formation is a potential side effect of prolonged hyperbaric therapy and is discussed with patients. It has been found that new cataracts can develop and existing cataracts may worsen. Unfortunately this condition of lens opacity (reduction in light reflective properties) does not reverse itself and may require surgery for repair.

There are ocular contraindications to hyperbaric oxygen therapy. Patients who have had placement of an orbital prosthesis called a hollow silicone orbital implant should not be exposed to changing ambient pressures. There is a potential for a pressure-induced collapse of the prosthesis in this case. Fortunately the hollow design is rarely used today. The second contraindication is an intraocular gas bubble when introduced by surgeons as an internal stent to maintain position of the retina. In this case an air space in the eye can change in volume and cause barotrauma. However, if the gas bubble is due to decompression sickness, hyperbaric treatment is still indicated. Another relative contraindication is with patients who have a history of optic neuritis. Although very rare, blindness has been reported anecdotally in this group of patients. One might think that glaucoma is a contraindication but it is not. This disease is marked by increased pressure in the eyeball that can lead to damage of the optic disk (area in the retina where the optic nerve enters the eye, also called the blind spot) and gradual loss of vision. In the case of refractive surgeries, hyperbaric oxygen therapy has not been shown to pose a problem.

There are differing opinions on the use and frequency of eye examinations in the hyperbaric setting. Drs. Butler and Hagan in "Physiology & Medicine of Hyperbaric Oxygen Therapy", recommend a pretreatment eye examination for any patient when a large number of treatments are indicated. The eye exam should consist of checking for changes in visual acuity, refraction, color vision, and status of the lens. A fundus (part of eye opposite the pupil) exam should also be performed. Other references appear to pay less attention to the use of ophthalmologist examinations in the hyperbaric setting and therefore I think this is a topic that deserves more discussion to guide hyperbaric center practices.

The last point to be made is that patients must be made aware of the potential effects that treatment may have on their vision. This should be an important topic in patient education and also a part of the signed patient consent. In most cases, vision changes are temporary and reversible and are not contraindications for therapy.

by Kenneth Capek RRT, CHT, MPA

Ken Capek, RRT, CHI, MPA is Director of Respiratory Care and Hyperbaric Oxygen Therapy at Englewood Medicai Center in Englewood, NJ. He can be reached at
COPYRIGHT 2008 Focus Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Capek, Kenneth
Publication:FOCUS: Journal for Respiratory Care & Sleep Medicine
Date:Nov 1, 2008
Previous Article:Bronchopleural fistula: a brief review.
Next Article:Sequal technologies names Randy Steward as Chief Operating Officer.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters